Evidence map›Paper›PMID 42138259›Full record

ArticleJournal of global health2026

Economic impact of heart failure in Brazil.

Nathalia Volpi E Silva, Daniela Vicentini, Renato Lima Vitorasso, Vicky Nogueira-Pileggi, Elizabeth Bilevicius, Vivian Cardoso Batista, Renato Mantelli Picoli

Abstract read
In one paragraph

Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathalia Volpi E SilvaOracle Life Sciences, São Paulo, Brazil.
Daniela VicentiniOracle Life Sciences, São Paulo, Brazil.
Renato Lima VitorassoOracle Life Sciences, São Paulo, Brazil.
Vicky Nogueira-PileggiOracle Life Sciences, São Paulo, Brazil.
Elizabeth BileviciusResearcher, Development and Medical Affairs, Viatris, São Paulo, Brazil.
Vivian Cardoso BatistaResearcher, Development and Medical Affairs, Viatris, São Paulo, Brazil.
Renato Mantelli PicoliOracle Life Sciences, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Heart failure (HF) is highly prevalent worldwide and is the main cause of hospitalisations in developed countries. It is the leading cause of hospitalisations for cardiovascular diseases in Brazil, which places a substantial burden on the Unified Health System. We aimed to evaluate public healthcare expenditures for patients diagnosed with HF and those potentially at risk of developing the condition. Methods: We used data from the DATASUS database, which encompasses information from the Brazilian Unified Health System (Sistema Único de Saúde (SUS)). We utilised the Outcome Information System Ambulatory - SUS (Sistema de Informações Hospitalares do SUS (SIA-SUS)) and the Hospital Information System - SUS (Sistema de Informações Hospitalares do SUS (SIH-SUS)) systems. After evaluating public health expenditures for patients with or at risk of developing HF, we analysed the distribution of these expenditures according to demographic factors and clinical characteristics to determine the financial impact on the healthcare system and its relationship with different patient profiles. Results: The SIA-SUS comprised 354 171 patients diagnosed with HF, while the SIH-SUS contributed 708 161 patients as a potential HF group. We linked 67 539 patients from SIA-SUS and SIH-SUS due to the need for a proxy identifier. Overall, potential HF patients incurred higher costs than diagnosed HF patients, with this disparity being particularly evident in hospital-related expenses. From 2018 to 2019, the average costs for potential HF patients were 1.7 times greater than those for diagnosed HF patients. Potential HF patients incurred the highest cost per patient across all age groups, with those ≤44 years old incurring the highest costs (USD 501.04), followed by those 45-64 years old (USD 488.76). Group diagnosed with HF, patients aged 45-64 years incurred the highest costs (USD 419.89), followed by those aged ≥65 (USD 330.02). Males incurred the highest costs in both diagnosed and potential HF groups. Conclusions: The burden of potential HF was higher than diagnosed HF, showed by greater public healthcare expenditures. Understanding the cost of this disease is important for informing resource allocation and the implementation of more effective measures for the population with HF.

Indexed as

Cost of IllnessHealth ExpendituresHeart FailureAdultAgedBrazilFemaleHospitalizationHumansMaleMiddle Aged

Identifiers

PMID42138259
PMCPMC13178058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.